251. The evaluation of bone metabolism in children with renal transplantation.
- Author
-
Büyükkaragöz B, Bakkaloglu SA, Kandur Y, Isiyel E, Akcaboy M, Buyan N, and Hasanoglu E
- Subjects
- Adolescent, Anthropometry, Biomarkers metabolism, Bone and Bones pathology, Case-Control Studies, Child, Child, Preschool, Female, Fibroblast Growth Factor-23, Fibroblast Growth Factors metabolism, Humans, Immunosuppressive Agents therapeutic use, Male, Osteoprotegerin metabolism, Parathyroid Hormone metabolism, RANK Ligand metabolism, Renal Insufficiency blood, Renal Insufficiency pathology, Vitamin D analogs & derivatives, Vitamin D metabolism, Young Adult, Bone Density, Bone and Bones metabolism, Kidney Transplantation, Renal Insufficiency surgery
- Abstract
This study aims to evaluate BMD and bone biomarkers and to investigate the effects of immunosuppressives on bone disease after RTx. Thirty-three RTR aged 16.7 ± 3.7 yr and healthy controls (n = 32) were enrolled. There was no difference between pre-RTx BMD and BMD at the time of study (45.9 ± 30.9 months after RTx), while both values were lower than controls (p < 0.01 and p < 0.05, respectively). Worst BMD scores were obtained at sixth month after RTx (-0.2 ± 0.9) and best at fourth year (1.4 ± 1.3). 25-hydroxy-(OH) vitamin D and OPG were higher in RTR (p < 0.001). BMD z scores negatively correlated with OPG and cumulative CS doses at the time of study (r = -0.344, p < 0.05 and r = -0.371, p < 0.05, respectively). Regression analysis revealed OPG as the only predictor of BMD (β -0.78, 95% CI -0.004 to -0.013, p < 0.001). The increase in OPG, a significant predictor of BMD, could either be secondary to graft dysfunction or for protection against bone loss. CS doses should be minimized to avoid their untoward effects on bone metabolism., (© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF